The Global Health Body Issues Alert Over Severe Scarcity of Weight-Loss Jabs
Under a tenth of patients who could benefit from obesity jabs like Wegovy are able to get them, states the WHO as it releases its inaugural recommendations on the medications.
Considering in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for more widespread and fairer access to GLP-1 medication.
Based on forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken.
"Our latest guidelines acknowledges that excess weight is a long-term condition that can be addressed with holistic and continuous treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are major obstacles to widespread access to the jabs that can help people shift significant body mass, says the body.
Weight-Loss Drug Supply Crisis
Despite the current best projected scenario, the supply of GLP-1 therapies might only reach about 100 million people – fewer than 10% of the global need, according to the WHO.
The recommendation calls on nations and manufacturers to increase access, via strategies including licensing agreements.
Exclusive production rights on a key compound – the core ingredient of the drug Wegovy – is scheduled to end in several countries in 2026.
How Obesity Drugs Work
These medications mimick a natural hormone to delay gastric emptying, curb appetite and boost satiety so individuals eat less.
People usually begin shedding pounds after several weeks of beginning the regular doses.
Evidence points to people may see weight return a year later of discontinuing the treatment, as their typical food cravings resume.
To be overweight or obese raises your risk for experiencing diseases, including diabetes, cardiovascular issues, brain attack, and some malignancies.
Obesity concerns people in countries worldwide and was linked to over three and a half million fatalities worldwide in 2024, per the WHO.
